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Abstract
Background: The goal of this study is to evaluate the status and future perspectives of clinical trials on positron
emission tomography in prostate cancer for diagnostic or therapeutic as well as for surveillance purposes.
Methods: The www.ClinicalTrials.gov database was searched on the 20th of January 2017 for all trials
containing terms describing “prostate cancer” (prostate, prostatic, malignant, malignancy, cancer, tumor) and
“positron emission tomography”. In total 167 trials were identified. Trials that included diseases other than PCa
were excluded (n = 27; 16%). Furthermore, we excluded trials (n = 4, 2%) withdrawn prior to first patient
enrollment. The remaining trials (n = 137, 82%) were selected for further manual classification analysis.
Results: One hundred thirty-seven trials were detected and analyzed. Majority of trials were in “active”
recruitment status (n = 46, 34%) followed by trials that had been “completed” - (n = 34, 25%) and trials with
“closed recruitment but active follow-up” (n = 23, 17%). Phase 1 and 2 comprised 46% of the complete trial
portfolio. Locally confined disease was of major interest (n = 46, 34%), followed by metastatic disease – not
otherwise specified (n = 43, 13%). Evaluation of PET was the primary goal of the trial in 114 (83%) cases. Most
of the trials evaluated only one agent (n = 122, 89%). Choline and PSMA represented two major groups (total
50%) and they were equally distributed across trial portfolio with 25% (n = 34) each. PSMA trials showed the
highest average annual growth rate of 56%. The trials were conducted in 17 countries.
Conclusion: The scientific community is showing a strong and ever-growing interest in the field and we
expect that in the coming years, more phase III trials will be initiated ultimately delivering the required Level
1 evidence.
Keywords: Cancer of prostate, Cancer of the prostate, Neoplasms, prostate, Neoplasms, prostatic, Prostate cancer,
Prostate neoplasms, Prostatic cancer, Positron emission tomography, Positron emission, Pet
Background
Prostate cancer (PCa) represents the most common can-
cer in men and the third most common cause of cancer
death [1]. Most newly diagnosed patients have localized
PCa which can be effectively treated using a number of
different treatment modalities [1]. Nevertheless, in the
high-risk disease setting and in the presence of metastasis
[1] despite the usage of a combination of treatment mo-
dalities a significant number of PCa patients progress, ul-
timately leading to death.
For local treatments such as radiation therapy and sur-
gery, exact knowledge of the localization and extend of
the disease is a prerequisite for optimal treatment.
Current practice requires the usage of multiple imaging
modalities for staging but also for optimal treatment se-
lection and planning. As such, multiparametric magnetic
resonance imaging (mpMRI) has been shown to be very
helpful in assessing the prostate and regional lymph
nodes [2]. In addition, positron emission tomography
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(PET) has been introduced as a functional imaging mo-
dality and is usually combined with computed tomog-
raphy (PET/CT) or magnetic resonance imaging (PET/
MRI). Although early experience using the traditional
agent, fluorodesoxyglucose (FDG), which has already
been successfully used in other tumor entities, was dis-
appointing [3], during the last decade several other
agents (e.g. FDG) using different pathways were devel-
oped and introduced to our daily clinical practice. Most
recently the prostate-specific membrane antigen (PSMA)
was recognized as a highly promising target both for
diagnostic and therapeutic purposes. Although, sufficient
evidence for utilization of PSMA or Choline PET in cer-
tain clinical situation is available, because of the associ-
ated costs, reimbursement has been an issue in several
countries limiting a more extensive usage.
Our daily work and decision-making should ideally be
based on results gained through well designed, properly
conducted clinical trials, either interventional or observa-
tional. Ideally, new knowledge should be reported and dis-
seminated to the scientific community through scientific
publications. Unfortunately, this is not always the case
and a great number of data remains unpublished with a
substantial time being required from completion of a
given trial to final publication. For these reasons, numer-
ous governments, international regulatory bodies as well
as the international committee of medical journal editors
demand registration of the interventional trials in one of
the clinical trial registries recognized by the World Health
Organization (WHO). Clinical trial registries are valuable
tools for information sharing and meta-research [4, 5].
They provide insights into the current research interests,
while also pointing to the areas where optimization in the
research portfolio is urgently needed [6–8].
As a relatively new entity in the PCa armamentarium,
interventional clinical trials on PET are of special inter-
est. A description of conducted and currently ongoing
clinical trials will provide clinicians and researchers with
the possibility to gain insights into the current state of
art of scientific activities.
Therefore, the goal of this study was to evaluate the
current status and future perspectives of clinical trials
on PET in PCa for diagnostic or therapeutic as well as
for surveillance purposes.
Methods
The www.ClinicalTrials.gov database was searched on
the 20th of January 2017 for all trials containing terms
describing “prostate cancer” (prostate, prostatic, malig-
nant, malignancy, cancer, tumor) and “positron emission
tomography” (positron, PET – case insensitive search).
In total 167 trials were retrieved. All available results
were downloaded in the form of xml files. Afterwards, a
database was designed and all of the data within the xml
files were imported to facilitate further data cleaning,
classification and management.
Trials that included diseases other than PCa were ex-
cluded (n = 27; 16%). Furthermore, we excluded trials (n
= 4, 2%) withdrawn prior to first patient enrolment. The
remaining trials (n = 137, 82%) were selected for further
manual classification analysis.
Firstly, we classified trials according to the primary role
of PET in the trial into 2 main categories: 1) Evaluation of
PET was the primary goal of a trial, and 2) Utilization and
evaluation of PET was optional or a secondary goal of the
trial. All reported PET agents were classified based on the
mechanisms of action and positron emitter.
Furthermore, we classified the trials according to dis-
ease characteristics into 5 categories: locally confined
disease, biochemical recurrence, metastatic PCa - not
otherwise specified (NOS), trials that include all prostate
cancer patients regardless of disease characteristics, and
castration-resistant PCa [9].
The goal of the trials was also evaluated according to
the role of PET imaging and categorized in 6 classes:
Post Treatment Follow-Up, Primary Tumor Evaluation,
General Staging, General Staging with Emphasis on
Nodal Status, Treatment Response Evaluation and Other
or Unknown. In cases where trials fulfilled the criteria
for more than one group, a trial was categorized in one
of the categories by consensus (EVB and NC).
Primary sponsors were categorized as follows: Aca-
demic, Industry, State Sponsored, Collaborative Groups,
and Foundations. Source of monetary support was deter-
mined by using the modified methodology of Hirsch et
al. [10, 11] as described in Cihoric et al. [5].
To evaluate which disciplines, lead the registered studies
on PET utilization in PCa we identified and analyzed the
reported contact data of the “Overall Study Officials”
(OSO). OSOs are defined as “Person(s) responsible for the
overall scientific leadership of the protocol, including study
principal investigator”. In a subsequent step we performed
an online search of each identified OSO for their respective
current affiliation and declared specialization. For the on-
line search PubMed, Google Scholar and the generic Goo-
gle search engine were utilized. If the OSO reported more
than one specialization or board certification we selected
the one that corresponded to their current institution.
Additionally, trials were analyzed across the reported
design elements, current recruitment status and results
availability.
Results
At the time of data acquisition the majority of trials were
in “active” recruitment status (n = 46, 34%) followed by tri-
als that had been “completed” - (n = 34, 25%) and trials
with “closed recruitment but active follow-up” (n = 23,
17%). Eleven (8%) trials were registered but did not start
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recruitment. Status was “unknown”, “available”, “enrolling
by invitation” and “approved for marketing” in 8 (6%), 3
(2%), 3 (2%) and 1(1%) trial respectively. Seven (5%) trials
were terminated, 3 trials due to insufficient recruitment, 1
due to lack of efficiency, 1 due to methodological reasons,
1 for “business reasons”, and 1 due to “the principal inves-
tigator leaving the institution”. One (1%) trial was sus-
pended for preliminary data analysis.
The trials were conducted in 17 countries within 135
recruitment sites. United States (n = 82, 61%) and
Canada (n = 17, 13%) were the countries with the most
recruitment sites (n = 99, 73%), followed by Denmark (n
= 6, 4%), the United Kingdom (n = 5, 4%), France (n = 4,
3%), Norway (n = 4, 3%) and Switzerland (n = 3, 2%).
Austria, Finland, Italy and the Netherlands each had 2
(1%) recruitment sites. Australia, China, Germany, India,
republic of Korea and Sweden had 1 (1%) recruitment
site each. The characteristics of all 137 trials are summa-
rized in Table 1.
Interventional and expanded access studies comprised
most of the clinical trials portfolio (n = 121, 88%). Most of
the trials were in an early phase. Phase 1 and 2 comprised
46% of the complete trial portfolio. Forty-three (31%) trials
did not contain information on the research phase. Inter-
ventional trials design data are presented in Table 2.
We have detected 16 (12%) observational trials, mostly
prospective by nature of data collection (n = 14, 10%), one
(1%) cross-sectional and one (1%) retrospective. Observa-
tional model was case-only in 7 (5%), cohort in 6 (4%) and
case-control in 2 (1%). Thirteen (9%) trials have one ob-
served group and 3 (2%) have two observed groups.
Locally confined disease was of major interest (n = 46,
34%), followed by metastatic disease – not otherwise
specified (n = 43, 13%). Trial distribution according to
the disease characteristics is shown in Fig. 1a. Primary
tumor evaluation and staging with emphasis on nodal
disease was the focus of 46 (34%) studies (Fig. 1b).
Evaluation of PET was the primary goal of the trial in
114 (83%) cases. In 22 trials (16%) PET evaluation or
utilization was optional. Sixteen (12%) trials explicitly
evaluated a combination of MRI and PET, and in 8 (6%)
PET/MRI was optional. Other trials did not mention
specific equipment (n = 113, 82%).
Most of the trials evaluated only one agent (n = 122,
89%), while 15 (11%) trials included more than one
agent. Choline and PSMA represented the two major
groups (total 50%) and were equally distributed across
the trial portfolio with 25% (n = 34) each. Trials with
other agents comprised 50% (n = 69) of the portfolio.
Four (3%) trials did not report on the type of PET agent
investigated. In total 5 different radionuclides were
used for labeling, namely, 11C, 18F, 68Ga, 89Zr and 64Cu.
Fifteen (11%) trials evaluated or allowed more than one
PET agent within a study, but only 3 (2%) trials
compared two agents directly. In total, 35 PET agents
were evaluated. The list of all used agents is shown in
Table 3.
PSMA trials showed the highest average annual
growth rate of 56% followed by choline (44%) and other
PET agents (7%). The average annual growth rate of
newly started trials during 2005 and 2017 was 35%. The
number of newly registered trials per year according to
Table 1 Clinical Trial Characteristics
Primary Purpose of a Trial
Diagnostic 93 68%
NRa 20 15%
Treatment 17 12%
Screening 3 2%
Other 2 1%
Basic Science 2 1%
Trial has data monitoring comity?
No 53 39%
Yes 60 44%
NRa 24 18%
Number of collaborators
0 78 57%
1 43 31%
2 12 9%
3 4 3%
Number of recruitment centers per trial
1 125 91%
2 2 1%
3 2 1%
NRa 8 6%
Trial duration in years - Median (Range) 3 years (1–21)
Year of last database entry update
≤ 2014 13 9%
2015 13 9%
2016 39 28%
2017 72 53%
Trials with results submitted to the ClinicalTrials.gov 14 10%
Number of patients
0–25 47 34%
26–50 27 20%
50–100 22 16%
101–200 22 16%
200–300 10 7%
301–400 1 1%
> 401 4 3%
NRa 4 3%
aNR not registered
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the evaluated agent is shown in Fig. 2. Academic centers
were the most common primary sponsors (n = 112,
82%). The financial support from collaborative groups
was limited to 5 trials only and state agencies acting as a
co-funder of a study were detected in 28 trials (20%).
Details on primary sponsors and source of funding are
shown in Fig. 3.
74% (101) of all trials reported on the trial overall official
(person responsible for overseeing of the protocol). Of
those, the most common specialization was nuclear medi-
cine (n = 38, 28%), followed by medical oncology (n = 25,
18%), radiology (n = 13, 9%), and radiation oncology (n =
12, 9%). Other specialties and non-clinical personnel were
represented by 8 principal investigators. Urology was rep-
resented by 5 (4%) trial principal investigators.
Discussion
Since its discovery, PET promised to be a powerful tool
for cancer diagnostics and treatment. In a short amount
of time, it managed to deliver and even exceeded the ex-
pectations in several diseases, with many notable exam-
ples in the field of oncology, such as lymphomas, lung
or head and neck cancers [12–15].
There is an increased interest in integrating PET/CT in
the management of PCa. Though initial attempts failed to
bring the expected results thus integrating PET/CT in the
diagnosis and treatment algorithms of PCa, the recent
United States Food and Drug Administration (FDA) ap-
proval of fluciclovine (18F) as well as new advances such
as the discovery of the Prostate-specific membrane anti-
gen (PSMA), a well-characterized imaging biomarker, have
brought this imaging modality back into the spotlight.
Our analysis showed that trials evaluating PET in PCa
patients are predominantly early phase, single arm and
open label, with more than 50% of all being small trials in-
cluding less than 50 patients. It seems that the investiga-
tions in PET and PCa mimics those for the general
oncological trials portfolio, where the early phase trials
with low patient number dominate [10]. The issue of trial
cost is well known, but this can be easily addressed by glo-
bal collaborative efforts as it has with most tumor entities
and imaging modalities. In the case of PET this is hard to
achieve due to several reasons, such as the price of pro-
duction and transport, regulatory environments and logis-
tic reasons like the short life of positron emitters.
In addition to the general overview, specific trials de-
serve special mention. Two trials on fluciclovine PET/
CT which have led to the FDA approval for diagnostic
purposes in men with suspected PCa recurrence have a
significant role in recognizing PET as a useful diagnostic
method. The first trial compares fluciclovine PET/CT
with the (111) In-capromab pendetide single photon
emission computerized tomography. Results were con-
trolled with biopsy (NCT00562315) [16]. The second
Table 2 Clinical Trial Design Data
Study type
Interventional 117 97%
Expanded Access 4 3%
Trial phase
NR 43 36%
Early Phase 1 6 5%
Phase 1 15 12%
Phase 1/Phase 2 13 11%
Phase 2 29 24%
Phase 2/Phase 3 7 6%
Phase 3 7 6%
Phase 4 1 1%
Allocation
NR 113 93%
Non-Randomized 18 15%
Randomized 6 5%
Interventional model
Single Group Assignment 102 84%
Parallel Assignment 14 12%
NR 20 17%
Crossover assignment 1 1%
Masking (Blinding)
Open Label 96 79%
NR 21 17%
Masked (Blinded) 4 3%
Number of arms
1 96 79%
2 11 9%
3 7 6%
NR 7 6%
Number of reported primary outcomes
NR 4
1 88
2 11
3 10
≥ 4 8
Number of reported secondary outcomes
NR 44
1 32
2 13
3 6
≥ 4 26
NR not regsitered
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one compared fluciclovine with choline PET. Fluciclo-
vine was superior to choline in terms of staging of pa-
tients with biochemical relapse [17]. This makes
fluciclovine the only tracer with high level evidence data
and the de-facto standard for future trials in these clin-
ical settings. Another noteworthy trial on fluciclovine is
a retrospective observational trial with 714 patients
sponsored by the manufacturer - Blue Earth Diagnostic
(NCT02443571), where the primary endpoint is safety
and secondary endpoint detection rate, sensitivity and
specificity and negative predictive value in biochemically
recurrent PC.
Phase III trials are of special interest, in general most
evidence is generated from them and they serve as a
polygon for eventual changes in clinical practice. In the
case of PET and PCa, they are indeed rare. Of those
registered in the ClinicalTrials.gov database, 3 trials
evaluate choline, 6 PSMA based agents, 3 fluciclovine
and 3 other agents. While the fluciclovine trials have
already completed recruitment, PSMA phase III trials
results are still recruiting. Completion of trials is ex-
pected in the coming years. One trial in 2018 -
NCT02981368, one in 2023 - NCT03001869 and three
in 2020 - NCT02659527, NCT02678351 and
NCT02919111. Important characteristics of PSMA trials
are more focused on local disease and nodal status.
However, there is no direct comparison of the different
agents or other PET tracers or diagnostic methods that
may cover local and systemic disease.
However, the goal of our study is not to discuss the
historical utilization of individual PET agents, but in-
stead to shed some light and create an overview of
current research efforts on a macro scale, which could
potentially provide insights into possible future direc-
tions and research areas currently underresearched and
in need of effort intensification.
Initiative for the trials on PET and PCa comes almost
exclusively from academic institutions, hence the finan-
cial burden mostly lies on the shoulders of individual in-
vestigator centers. Having in mind financial burden and
logistic limitation it is not highly probable that the aca-
demic community will conduct multi-centric phase III
trial with a high number of patients for one specific
therapy-oriented endpoint. Instead, the community may
focus its efforts towards an organization of high quality
observational trials. An observational trial, although pre-
cipitated as lower quality investigation, represents an im-
portant tool in addressing important medical questions
[18]. The importance of observational trials and theoret-
ical basis is well described in the work of Williams RJ et
al. [19] and Choi BC et al. [20].
Our trial portfolio showed a lack of international col-
laborations. A potential solution, would be a conglomer-
ation of the individual interest groups achieving both a
reduction of expenses and a reduction of wasted re-
sources. This includes detection of common interests,
collaborative efforts and data sharing. A successful ex-
ample of collaborative efforts in oncology, where results
resulted to practice changing, is the EMBRACE Study –
“An international study on MRI-guided Brachytherapy
in locally Advanced Cervical cancer” [21].
An important aspect of a study is the detection of the
growing interest in PET and prostate research. The
growth in the number of newly registered trials may be
explained by the strengthened regulatory environment
when it comes to registration of interventional trials.
However, ICMJE (International Committee of Medical
Journal Editors) recommendations and regulations exist
for over 10 years and interventional trial registration is
obligatory in the USA since 2007. A significant quantita-
tive “jump” is only seen during the last 3 years. This may
be attributed to the ever-growing importance of
Fig. 1 Distribution of trials based on disease characteristics and role of PET within a trial. (a) Trial distribution according to the disease characteristics.
(b) Trial distribution according to the goal of PET examination
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Table 3 List of detected positron emission tomography agents
Positron Emission Tomography
Agent as Stated in ClinicalTrials.gov
Radionuclid IUPAC name of the carrier or other relevant source Number
of trials
Acetate (11C)a Acetate 22
Choline (11C)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 16
Choline (18F)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 37
Choline NOSa 2-Hydroxy-N,N,N-trimethylethan-1-aminium 7
Citrate (68Ga) 2-Hydroxypropane-1,2,3-tricarboxylic acid 1
DFO-huJ591 (89Zr) Recombinant humanized monoclonal antibody
J591 conjugated to chelator desferrioxamine B
1
DFO-MSTP2109A (89Zr) Desferrioxamine - DFO-MSTP2109A is an
antibody that works against STEAP1 - found
on the surface of prostate cancer cells
1
DHT (18F)a (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,
13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-
tetradecahydrocyclopenta[a]phenanthren-3-one
3
DOTA-Bombesin (68Ga) 68Ga-DOTA-Bombesin is a gallium-68-labeled
gastrin-releasing peptide receptor (GRPr)
antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)
-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.
1
DOTATET (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic a
cid (also known as DOTA)
1
FAZA (18F) Nitroimidazole nucleoside analogue 1-(5-fluoro-5
-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole (FAZA)
2
FDG (18F)a 2-Deoxy-2-[18F]fluoroglucose 15
FLT (18F) 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]
-5-methylpyrimidine-2,4-dione
1
Fluciclovine (18F) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 13
Fluciclovine (NOS) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 1
Fluorocholine (18F) Fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride 1
FMAU (18F) 2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-D
-arabinofuranosyluracil (fluorine F 18 d-FMAU
[18F-FMAU]),
3
MeAIB (NOS)a 2-methyl-2-(methylamino)propanoic acid 1
Methionine (11C)a (2S)-2-amino-4-methylsulfanylbutanoic acid 3
MISO (18F) 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol 1
NaF (18F)a Sodium;fluoride 20
NODAGA-MJ9 (Ga-68)a 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic
acid (NODAGA)
1
NOTA-BBN-RGD (68Ga) 1,4,7-triazacyclononanetriacetic acid (NOTA),
Arg-Gly-Asp (RGD) and bombesin (BBN)
1
P15–041 (68Ga) Unknown 1
PACAP (64Cu) Pituitary adenylate cyclase-activating peptide 2
Peripheral Benzodiazepine Receptor-28 (11C) Peripheral Benzodiazepine Receptor-28 1
PSMA DCFPyL (18F)a N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]
-4-[18F]fluorobenzyl-L-cysteine ([18F]DCFBC)
21
PSMA (68Ga) Glutamate carboxypeptidase II, also known
as N-acetyl-L-aspartyl-L-glutamate
peptidase I
15
PSMA (89Zr) Glutamate carboxypeptidase II, also known as
N-acetyl-L-aspartyl-L-glutamate peptidase I
2
PSMA CTT 1057 (NOS) Cancer Targeted Technology (CTT), a privately
held Seattle-based biotechnology firm that will
develop the agent, CTT1057. CTT1057 is a small
1
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metabolic imaging in diagnostics and treatment of PCa
patients. It is also possible that public awareness is grow-
ing, and the scientific community is addressing the need
for high quality data.
An interesting observation made during this study
was a lack of any kind of comprehensive registry
where the agents may be searched or evaluated across
their type, mechanism of action or by any other
means. The data entries in ClinicalTrials.gov are not
sufficient and classification of the agents demands ex-
tensive manual work. The problem of resource identi-
fication and categorization is well recognized across
other biomedical disciplines and it resulted in the
Force11 initiative [22, 23].
Our analysis has some limitations including the possi-
bility that some interventional prospective trials were
not registered within the ClinicalTrials.gov or are not
registered at all. However, ClinicalTrials.gov is the lar-
gest and most accurate registry to date, and we strongly
believe that our results reflect the current state of current
and past clinical trials worldwide. Furthermore, during trial
classification we were forced to reduce the total number of
possible combinations to a reasonable number of groups.
For example, in one trial the investigators stated that the
trial goal was staging in metastatic setting, but as an add-
itional primary goal they correlated the tumor Gleason
score with PET intensity. A complete annotated dataset is
available for download (Additional file 1). Primary and
secondary endpoints are also available (Additional file 2).
Despite these limitations, our analysis provides an ac-
curate description of the scientific activity on the use of
PET in clinical trials involving PCa patients.
Conclusion
There is a growing interest in PET utilization in PCa. How-
ever, prospective trials investigating PET in PCa, especially
those that may generate higher evidence level, are in gen-
eral rare. Nevertheless, the scientific community is showing
Table 3 List of detected positron emission tomography agents (Continued)
Positron Emission Tomography
Agent as Stated in ClinicalTrials.gov
Radionuclid IUPAC name of the carrier or other relevant source Number
of trials
molecule that homes in and binds irreversibly to
prostate specific membrane antigen (PSMA)
PSMA DCFBC (18F) (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-
fluorobenzyl-L-cysteine) (F-DCFBC)
4
PSMA Df-IAB2M (89Zr) Zr-89-desferrioxamine-IAB2M 1
RM2 (68Ga) 68Ga-RM2 stands for Galium-68 labeled DOTA-4-
amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-
Ala-Val-Gly-His-Sta-Leu-NH2
3
Sodium Fluoride (18F) Sodium Fluoride 1
uPAR NOTA (68Ga) Urokinase Plasminogen Activator Receptor 1
aAgent was an optional or was compared to other agent in more than one trial
Fig. 2 Primary sponsors and source of funding
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a strong and ever-growing interest in the field and we ex-
pect that in the coming years, more trials will be initiated
ultimately delivering the required Level 1 evidence.
Additional files
Additional file 1: Annotated Dataset. (XLSX 54 kb)
Additional file 2: Trials Endpoints. (XLSX 56 kb)
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